This section collates all currently available data relevant to therapeutic development in Timothy Syndrome. It is designed to allow industry reviewers to rapidly understand the depth, quality, and development-readiness of existing evidence, and to identify where collaboration could accelerate progress.
Disease-causing variants
A structured overview of known pathogenic and likely pathogenic CACNA1C variants associated with Timothy Syndrome and CACNA1C-Related Disorders, including variant type, location within the channel, and reported phenotypic consequences. Where available, genotype–phenotype correlations are summarised to support patient stratification considerations. These data will be incorporated into the upcoming TSA CACNA1C Portal.
Mechanistic pathophysiology
Summary of current understanding of Cav1.2 channel dysfunction, downstream calcium-handling abnormalities, and their relevance to cardiac electrophysiology and neurodevelopment. This section highlights mechanistic hypotheses that are directly actionable for therapeutic modulation.
Industry relevance
Target validation, modality selection, translational relevance.
In vitro and cellular models
Overview of existing cellular systems used to study CACNA1C dysfunction, including induced pluripotent stem cell (iPSC)–derived cardiomyocytes and neuronal models, where available. Key findings related to channel kinetics and pharmacological modulation are summarised.
Translational gaps
Explicit identification of areas where additional preclinical work could strengthen development programmes, including opportunities for partner-supported model refinement or assay development.
Industry relevance
De-risking early R&D, translational strategy alignment.
Published case reports and series
Curated summary of peer-reviewed clinical publications describing Timothy Syndrome presentation, progression, interventions, and outcomes. Key limitations of existing literature (small N, heterogeneity) are clearly stated.
Treatment experience to date
Overview of historical and current therapeutic approaches, including anti-arrhythmics, device therapy, and supportive interventions, with emphasis on what has and has not demonstrated meaningful disease modification.
Industry relevance
Clinical baseline, unmet need, comparator context.
TSA patient registry overview
Description of registry scope, inclusion criteria, and data elements captured, including genetic confirmation, cardiac outcomes, neurodevelopmental measures, and longitudinal follow-up.
Emerging natural history insights
Summary of early patterns observed in registry data, including disease progression trajectories, event frequency, and phenotypic variability, presented at a high level without disclosing identifiable information.
Industry relevance
Feasibility assessment, endpoint selection, external control potential.
Electrophysiological biomarkers
Compilation of cardiac biomarkers relevant to Timothy Syndrome, including QTc metrics, arrhythmia burden, and rhythm variability, with notes on measurement feasibility and historical use.
Molecular and cellular biomarkers
Overview of exploratory molecular signals linked to CACNA1C dysfunction, including calcium-handling pathways, gene expression changes, and proteomic markers where available.
Functional and digital biomarkers
Description of patient-centred and digital measures under consideration, such as wearable-derived cardiac data and caregiver-reported outcomes.
Industry relevance
Pharmacodynamic readouts, surrogate endpoint development.
Clinical meaningfulness
Evidence and hypotheses linking biomarker changes to clinically relevant outcomes, including arrhythmic risk reduction and functional stabilisation.
Regulatory context
High-level discussion of how these biomarkers may support surrogate or intermediate endpoints under regulatory flexibility frameworks for ultra-rare and paediatric diseases.
Industry relevance
Endpoint justification, regulatory strategy.
Patient availability and recruitment
High-level overview of diagnosed patient numbers, geographic distribution, and TSA’s role in facilitating recruitment.
Feasible trial designs
Discussion of small-N, adaptive, Bayesian, and externally controlled trial designs appropriate to the available data and population size.
Industry relevance
Development planning, risk assessment.
Priority data gaps
Transparent identification of where current evidence is insufficient to support full development, including biomarker validation and longitudinal outcome correlation.
How industry can engage
Specific examples of how industry collaboration—through sponsored research, biobank expansion, or joint analysis—can address these gaps efficiently.
Industry relevance
Clear collaboration entry points.
Data use principles
Overview of ethical, consent, and governance frameworks governing registry and biobank data use.
Access pathways
Description of how data packages, summaries, or deeper analyses can be accessed under confidentiality agreement.
Industry relevance
Compliance, diligence readiness.
- Publication bibliography
- Data dictionaries (registry variables, biomarker definitions)
- Biobank sample inventory overview
- Ongoing and planned research activities
Final positioning statement
This Data and evidence section is intended to function as a living diligence asset – updated as new data emerge and aligned continuously with industry development needs. Its purpose is not to oversell maturity, but to enable informed, efficient collaboration grounded in scientific and operational reality.
Start a conversation
If you are exploring CACNA1C-Related Disorders as a potential area of interest, we are happy to talk. Early-stage, non-confidential discussions are welcome, and we can share more detailed data packages under a confidentiality agreement.